- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02776007
Patients Perceptions of Using the "Libre" System Compared With Conventional SMBG in Adolescents With Type 1 Diabetes The Libre Sat Trial
Patients Perceptions of Using the Libre System Compared With Conventional SMBG in Adolescents With Type 1 Diabetes The Libre Sat Trial
The Libre- flash glucose monitoring system is an episodic real-time data on demand device. This means that patients can measure their glucose level when they choose by scanning the device, while at the same time a sensor automatically measures and continuously stores glucose readings day and night. Every scan shows the current glucose reading and the last 8 hours of glucose. There are no alarms and the system does not require calibration.
In the present study we aim to evaluate treatment satisfaction and comfort using the Libre flash glucose monitoring system compared to conventional Self Measurement of Blood Glucose (SMBG) in adolescents with type 1 diabetes that discontinued using continuous glucose monitoring.
The second aim of the study is to evaluate the rate of use and the impact of Libre use compared to Self-Measurement of Blood Glucose among adolescents who are sub-optimally controlled and stopped using Continuous Glucose Monitoring. The study is an investigator initiated study, single-center, randomized, parallel study of 12 weeks with an optional cross-over 12 weeks extension period .
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Petach-Tikva, Israel, 49202
- Schneider Children's Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The subject has documented Type 1 Diabetes , as defined by the American Diabetes Association and World Health Organization for at least 1 year prior to study enrollment
- The subject used continuous glucose monitoring until 3 months or more before the study start
- Age 12-17 years
- The subject has an HbA1c value > 7.5% at time of screening visit
- The subject is willing to follow study instructions
- Subject is available for entire study duration
Exclusion Criteria:
- Concomitant diseases that influence metabolic control or other medical condition, which in the Investigator's opinion, may compromise patient safety
- Significant co-morbidity that, in the opinion of the investigators would preclude participation in the study
- Any significant diseases or conditions including psychiatric disorders and substance abuse that in the opinion of the investigator is likely to affect the subject's ability to complete the study or compromise patient's safety
- Subject is taking or has taken oral or parenteral glucocorticoids within 1 month prior to screening, or plans to take oral or parenteral glucocorticoids within the planned study duration. Exceptions: Short term oral or parenteral glucocorticoids up to 7 days
- Subject has known allergy to medical grade adhesives
- Subject is participating in another study of a medical device or drug that could affect glucose measurements or glucose management or receipt of any investigational medical product within 1 month prior to screening
- Female subject of child-bearing potential who have a positive pregnancy test at screening, is pregnant, breast-feeding, or planning to become pregnant within the planned study duration or is not using adequate contraceptive methods
- Subject diagnosed with current eating disorder such as anorexia or bulimia
- Subject has a history of one or more episodes of Diabetes Keto-Acidosis requiring hospitalization within a month prior to screening
- Subject has unstable or rapidly progressive renal disease or is receiving dialysis
- Subject has active proliferating retinopathy
- Subject has current or recent history of alcohol or drug abuse
- Subject has visual impairment or hearing loss, which in the Investigator's opinion, may compromise patient ability to perform study procedures safely
- Any disease or condition that may influence the HbA1C testing
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Libre Flash CGMS (Continuous Monitoring System)
Patients will use the Libre Flash Continuous Glucose Monitoring System for 12 weeks for their glucose Management
|
|
Active Comparator: SMBG
Patients will use Self-Monitoring of Blood Glucose for 12 weeks for their glucose management
|
Patients will use their personal glucose meter to perform Self-Measurement Blood Glucose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Diabetes Treatment satisfaction questionnaire
Time Frame: At the final visit- week 12
|
At the final visit- week 12
|
|
Libre-user evaluation questionnaire
Time Frame: At the final visit-week 12
|
20-item questionnaire that asses treatment satisfaction with the Libre including ease of use, comfort, pain, design and system operation.
The questionnaire will be scored to a final score integrating all items to a total score
|
At the final visit-week 12
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Glycemic control measured by HbA1c
Time Frame: At the final visit-week 12
|
At the final visit-week 12
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of blood glucose measurements at each arm
Time Frame: At the final visit-week 12
|
At the final visit-week 12
|
|
Number of flash glucose measurements at the intervention arm
Time Frame: At the final visit-week 12
|
At the final visit-week 12
|
|
Percentage of glucose sensor readings within the range of 70 to 180 mg/dl
Time Frame: At the final visit-week 12
|
At the final visit-week 12
|
|
Percentage of glucose sensor readings below 60 mg/dl
Time Frame: At the final visit-week 12
|
At the final visit-week 12
|
|
Percentage of glucose sensor readings above 240 mg/dl
Time Frame: At the final visit-week 12
|
At the final visit-week 12
|
|
Average of glucose sensor readings
Time Frame: Week 12
|
Average of glucose sensor readings (per 24 hours)
|
Week 12
|
Standard Deviation of glucose sensor readings
Time Frame: Week 12
|
Standard Deviation of glucose sensor readings (per 24 hours) ) |
Week 12
|
HbA1c change from baseline to the end of the first intervention period
Time Frame: At the final visit-week 12
|
At the final visit-week 12
|
|
HbA1c change from baseline to the end of the second intervention period
Time Frame: At the final visit-week 12
|
At the final visit-week 12
|
|
Average fasting blood glucose level
Time Frame: At the final visit-week 12
|
At the final visit-week 12
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RMC023516Ctil
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rabin Medical CenterDreaMed DiabetesTerminated
Clinical Trials on Libre Flash CGMS
-
Nanjing First Hospital, Nanjing Medical UniversityUnknown
-
Jessa HospitalUnknownFlash Glucose Monitoring | Skin ReactionsBelgium
-
Abbott Diabetes CareCompleted
-
Shanghai General Hospital, Shanghai Jiao Tong University...UnknownDiabetes Mellitus, Type 2 | Flash Glucose MonitoringChina
-
Abbott Diabetes CareCompleted
-
Jessa HospitalUnknownMetabolic Control | Flash Glucose MonitoringBelgium
-
Abbott Diabetes CareCompleted
-
Abbott Diabetes CareCompleted
-
Woodlands Health CampusTan Tock Seng HospitalRecruitingType 2 Diabetes Treated With InsulinSingapore
-
Abbott Diabetes CareTerminatedDiabetes MellitusUnited States